Welcome to India's first Website with complete information on Infectious deseases, Vaccines, Immunisation and Immunoglobulins. + + + Become a registered member of the site and recieve latest balanced information from the world of Vaccines.

Blog & Forum

  • Baby
  • Baby
  • Baby
  • Baby
  • Baby
  • Baby
  • Baby
  • Baby
  • Baby
  • Baby
  • Baby
  • Baby
  • Baby
  • Baby
  • Baby
  • Baby
  • Baby
  • Baby
  • Baby
  • Baby
  • Baby

Poll Manager

Suspension of Rotarix
 

Who's Online

We have 355 guests online

Statistics

Members : 234
Content : 368
Web Links : 19
Content View Hits : 586236
VACCINE INDIA
PDF Print E-mail

 

NASOVAC

 

DESCRIPTION
NASOVAC (Influenza Vaccine(Human,Live Attenuated)) Pandemic (H1N1), freeze dried is a live monovalent vaccine for administration by intranasal spray. The influenza vaccine contains Influenza virus cultivated on embryonated eggs.

COMPOSITION

[Propagated in Embryonated hen eggs (SPF)]
Each single dose of 0.5 ml contains:
A/17/California/2009/38 > 107EID50
Gelatin (Partially hydrolyzed) 2.5%, Sorbitol 5%, L-Alanine 0.1%, L-Histidine 0.21%, Tricine 0.3%, L-Arginine hydrochloride 1.6%, Lactalbumin hydrolysate 0.35%, Phosphate buffer saline Base
Reconstitute with Sterile Water for Inhalation USP. The vaccine contains no preservatives.
Dose: 0.5 ml intranasal (spray 0.25 ml per nostril). The tip attached to the sprayer is equipped with a nozzle that produces a fine mist that is primarily deposited in the nose and nasopharynx.

NASOVAC is supplied as a vial containing freeze-dried cake in USP type 1 glass vials. A ampoule/vial containing sterile water for inhalation as diluent, syringe (for reconstitution of multi dose vaccine vial), syringe (for administration) , needle free device and intranasal spray device are also supplied along with the vaccine.
The vaccine complies with the WHO recommendation and EU decision for the pandemic.

 
PDF Print E-mail

Dramatic Potential Of Rotavirus Vaccines

 

August 6, 2010, Path reports.

New studies reveal dramatic potential of rotavirus vaccines in Asia and Africa

Two new studies published today in the Lancet add to a growing body of evidence on the safety, efficacy, and lifesaving potential of rotavirus vaccines in low-income settings of Asia and Africa; where the virus takes its greatest toll.

The studies, co-sponsored by the PATH Rotavirus Vaccine Program and conducted at clinical research sites in Ghana, Kenya, Mali, Bangladesh, and Vietnam, found that rotavirus vaccines
 
PDF Print E-mail

Withdrawal of smallpox vaccine 'contributed to spread of HIV'

Ending smallpox vaccination may have contributed to the explosive spread of HIV, scientists have claimed. The suggestion follows laboratory studies showing the vaccine's powerful ability to curb the Aids virus. It may have offered protection to people in the early days of the HIV epidemic, the findings suggest. But this would have been removed once smallpox was eradicated and the vaccine withdrawn.

 

Smallpox immunisation was gradually phased out between the 1950s and 1970s. Since that time, rates of HIV infection have increased exponentially around the world. Scientists in the US studied white blood cells taken from people recently immunised with the smallpox vaccine, vaccinia. They found that immunisation led to a fivefold reduction in the ability of HIV to replicate in the cells.

 
PDF Print E-mail

Novel H1N1 Influenza: Resources for Clinicians

 

 

Guidance for Patient Management

 

Guidance for Specific Settings

 
PDF Print E-mail

Inactivated Poliovirus Vaccines (IPV)

PATH has released its study report on exploring feasibility of administrating IPV intradermally. Improving the Affordability of Inactivated Poliovirus Vaccines (IPV) for Use in Low- and Middle-Income Countries: An Economic Analysis of Strategies to Reduce the Cost of Routine IPV Immunization

This report presents results from an economic model that calculates the costs involved in delivering IPV vaccine in Indian immunization clinics according to three strategies: (1) intradermal delivery of reduced volumes of vaccine per dose,
 
PDF Print E-mail

 

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial

The FUTURE I/II Study Group

Correspondence to: J Dillner, Department of Medical Microbiology, Lund University, Malmö University Hospital, SE-20502 Malmö, Sweden This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Abstract

Objectives To evaluate the prophylactic efficacy of the human papillomavirus (HPV) quadrivalent vaccine in preventing low grade cervical, vulvar, and vaginal intraepithelial neoplasias and anogenital warts (condyloma acuminata).

 
PDF Print E-mail

 Recommendations for the Use of Rotavirus Vaccines

May 14, 2010

Summary

FDA is updating its recommendations on both Rotarix and RotaTeq, vaccines for the prevention of rotavirus disease in infants. Based on careful evaluation of a variety of scientific information, FDA has determined it is appropriate for clinicians and health care professionals to resume the use of Rotarix and to continue the use of RotaTeq.

Background

On March 22, 20101, FDA provided an early communication regarding Rotarix, manufactured by GlaxoSmithKline

 
PDF Print E-mail

Ministry admits lapses in HPV vaccine trial

TEENA THACKER NEW DELHI,

 

DR V M Katoch, Secretary, Department of Health Research has admitted to the Parliamentary standing committee on Health and Family Welfare that Drug Controller General of India (DCGI) guidelines were not adhered to in the clinical trial of the Human Papilloma Virus (HPV) vaccine.

 

A committee formed by the Union health ministry to probe the alleged violation of ethical guidelines is yet to submit its report.

 
PDF Print E-mail

 

SWINE FLU OUTBREAK

 

Recently, human cases of swine influenza A (H1N1) virus infection have been recently reported in several countries. This is a novel influenza A virus that has not been identified in people before, and human-to-human transmission of the virus appears to be ongoing and thus represents a real pandemic threat.

 

 
Cold Chain PDF Print E-mail

VACCINE COLD CHAIN

Vaccines are among the most sensitive drugs that are administered into the body of healthy individuals. They are sensitive to heat and freezing hence they must be stored at the correct temperature right from the time they are manufactured till they are administered. This system of storage of vaccine or the medicine is known as cold chain.

The potency of the vaccines can get affected irreversibly if the temperature is not maintained within the recommended range during the storage, transport, retailing and administering the vaccine.

 

The recommended temperature range for most of the vaccine is from 2°C to 8°C however the range varies for the storage and transport, even long storage and short storage temperature also varies. Few vaccines are stored at a frozen state.

 

Last Updated on Saturday, 27 June 2009 14:00
 
More Articles...